IRADIMED CORP has announced its financial results for the third quarter of 2026, showcasing a notable increase in revenue and profits. The company reported a revenue of $24.2 million, which reflects a 14% increase compared to the same period last year. This growth is attributed to the successful launch of their new MRI-compatible IV pump, which has been well-received in the market.

In addition to the revenue growth, IRADIMED also declared a quarterly cash dividend of $0.20 per share, payable on November 27, 2026. This decision underscores the company's commitment to returning value to its shareholders while continuing to invest in its growth strategies.

IRADIMED is a leader in the development of innovative medical devices specifically designed for use in MRI environments, including non-magnetic IV infusion pump systems and patient vital signs monitoring systems. The company operates within the Surgical & Medical Instruments & Apparatus industry, which is experiencing significant growth driven by advancements in medical technology and increasing healthcare demands.

According to the filing, the company’s net income for the quarter was $6.5 million, up from $5.6 million in the same quarter of 2025, marking a 17% increase. Earnings per diluted share also rose to $0.51, compared to $0.43 per share in the previous year. The company noted that the gross margin improved sequentially as production efficiencies were realized.

IRADIMED's President and CEO, Roger Susi, expressed optimism about the company’s future, stating, “We are pleased to report record revenue driven by the continued successful launch of our new 3870 MR IV pump. With record bookings and rapidly building momentum, we believe we are well positioned for a strong finish to the year.”

Looking ahead, IRADIMED anticipates revenue for the fourth quarter of 2026 to be between $25.0 million and $26.5 million, which would put the company on track to achieve a $100 million revenue run rate. The company has also revised its full-year revenue guidance, now expecting between $91.6 million and $93.1 million, as well as adjusted earnings per share forecasts.

As IRADIMED continues to innovate and expand its product offerings, the company remains a strong player in the surgical and medical instruments industry, which is expected to grow as healthcare providers increasingly adopt advanced technologies to improve patient care.

The filing does not say what happens next.